Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network

The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection

(2015) Benjamin P. Linas et al.   ANNALS OF INTERNAL MEDICINE

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

(2015) Soumitri Barua et al.   ANNALS OF INTERNAL MEDICINE

The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C

(2014) Zobair Younossi et al.   DIGESTIVE AND LIVER DISEASE

Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens

(2014) Zobair M. Younossi et al.   HEPATOLOGY

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

(2014) Eric Lawitz et al.   LANCET

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

(2014) Kris V. Kowdley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimating HCV Prevalence at the State Level: A Call to Increase and Strengthen Current Surveillance Systems

(2013) Rachel Hart-Malloy et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

(2011) Peter C. Austin   MULTIVARIATE BEHAVIORAL RESEARCH